AR048206A1 - Dispersiones de solidos amorfos de un inhibidor de la mtp para el tratamiento de obesidad - Google Patents

Dispersiones de solidos amorfos de un inhibidor de la mtp para el tratamiento de obesidad

Info

Publication number
AR048206A1
AR048206A1 ARP040104185A ARP040104185A AR048206A1 AR 048206 A1 AR048206 A1 AR 048206A1 AR P040104185 A ARP040104185 A AR P040104185A AR P040104185 A ARP040104185 A AR P040104185A AR 048206 A1 AR048206 A1 AR 048206A1
Authority
AR
Argentina
Prior art keywords
solids
amorph
dispersions
mtp inhibitor
obesity treatment
Prior art date
Application number
ARP040104185A
Other languages
English (en)
Spanish (es)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR048206A1 publication Critical patent/AR048206A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1688Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Indole Compounds (AREA)
ARP040104185A 2003-11-14 2004-11-12 Dispersiones de solidos amorfos de un inhibidor de la mtp para el tratamiento de obesidad AR048206A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51993103P 2003-11-14 2003-11-14

Publications (1)

Publication Number Publication Date
AR048206A1 true AR048206A1 (es) 2006-04-12

Family

ID=34590458

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040104185A AR048206A1 (es) 2003-11-14 2004-11-12 Dispersiones de solidos amorfos de un inhibidor de la mtp para el tratamiento de obesidad

Country Status (16)

Country Link
US (1) US20080293801A1 (https=)
EP (1) EP1696887A1 (https=)
JP (1) JP2007511500A (https=)
KR (1) KR20060096076A (https=)
CN (1) CN1878538A (https=)
AR (1) AR048206A1 (https=)
AU (1) AU2004289110A1 (https=)
BR (1) BRPI0416596A (https=)
CA (1) CA2545443A1 (https=)
CO (1) CO5690536A2 (https=)
IL (1) IL175372A0 (https=)
MX (1) MXPA06005489A (https=)
NO (1) NO20062778L (https=)
NZ (1) NZ546677A (https=)
TW (1) TW200515909A (https=)
WO (1) WO2005046644A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080068127A (ko) * 2005-12-15 2008-07-22 에프. 호프만-라 로슈 아게 피롤로[2,3-c]피리딘 유도체
WO2008090198A1 (en) * 2007-01-25 2008-07-31 Janssen Pharmaceutica Nv Use of mtp inhibitors for increasing levels of satiety hormones
EP2522657B1 (en) 2010-01-06 2016-08-03 Takeda Pharmaceutical Company Limited Indole derivative
US8313774B1 (en) 2012-06-26 2012-11-20 Magnifica Inc. Oral solid composition
EP3861989A1 (en) * 2020-02-07 2021-08-11 Bayer Aktiengesellschaft Pharmaceutical composition containing regorafenib and a stabilizing agent
US12453728B1 (en) 2024-08-08 2025-10-28 Redux Therapeutics, Llc Compositions comprising inhibitors of microsomal triglyceride transfer protein and Apo-B secretion

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4884235A (en) * 1988-07-19 1989-11-28 Thiele Alfred A Micromagnetic memory package
WO1992018106A1 (fr) * 1991-04-16 1992-10-29 Nippon Shinyaku Co., Ltd. Procede de production d'une dispersion solide
US5340591A (en) * 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
JP3265680B2 (ja) * 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
DE19504832A1 (de) * 1995-02-14 1996-08-22 Basf Ag Feste Wirkstoff-Zubereitungen
ES2287971T3 (es) * 1997-08-11 2007-12-16 Pfizer Products Inc. Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.
KR100575944B1 (ko) * 2001-06-28 2006-05-02 화이자 프로덕츠 인코포레이티드 미소체 트리글리세라이드 전달 단백질(mtp) 및/또는아포지방단백질 b(apo b)분비의 억제제로서의트리아미드-치환된 인돌, 벤조푸란 및 벤조티오펜
AR038375A1 (es) * 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo

Also Published As

Publication number Publication date
CN1878538A (zh) 2006-12-13
AU2004289110A1 (en) 2005-05-26
IL175372A0 (en) 2006-09-05
CO5690536A2 (es) 2006-10-31
BRPI0416596A (pt) 2007-01-30
TW200515909A (en) 2005-05-16
US20080293801A1 (en) 2008-11-27
JP2007511500A (ja) 2007-05-10
KR20060096076A (ko) 2006-09-05
NZ546677A (en) 2008-11-28
WO2005046644A1 (en) 2005-05-26
NO20062778L (no) 2006-08-14
MXPA06005489A (es) 2006-08-11
EP1696887A1 (en) 2006-09-06
CA2545443A1 (en) 2005-05-26

Similar Documents

Publication Publication Date Title
BRPI0501449A (pt) Mistura funcional, processos para curar e para curar parcialmente uma mistura funcional, e, adesivo
PE20050142A1 (es) 2-hidroxi-3-diaminoalcanos de benzamida
AR082343A2 (es) Un metodo de reduccion de desgaste por rozamiento para combustibles y procedimiento para preparar una composicion combustible
BRPI0609711B8 (pt) uso de uma solução aquosa com potencial redutivo oxidativo (orp)
MA34207B1 (fr) Inhibiteurs de la pi3 kinase et/ou du mtor
PE20040775A1 (es) DERIVADOS DE INDOL COMO AGONISTAS DE ADRENORECEPTORES ß2
BRPI0518222A (pt) composto, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3 e utilização dos mesmos
EA200501601A1 (ru) Соединения 1,2,4-оксадиазолбензойной кислоты и их применение
TW200505423A (en) Combination, kit and pharmaceutical composition for treatment of parkinson's disease
BRPI0710266B8 (pt) composto, medicamento, e, uso de um composto
BR0211274A (pt) Combinação de um antagonista de receptor de aldosterona e um inibidor de hmg co-a redutase
EA200400154A1 (ru) Новые лекарственные формы замещенного бензимидазола и способ их применения
BR0308955A (pt) Produto oral e composição
ATE478660T1 (de) Verwendung von rotigotin zur behandlung von depressionen
BRPI0519195A2 (pt) composiÇço de cuidado oral, e, mÉtodo para prevenir ou tratar cÁrie dental em um indivÍduo humano ou animal
AR048206A1 (es) Dispersiones de solidos amorfos de un inhibidor de la mtp para el tratamiento de obesidad
BRPI0515477A (pt) derivados heterocìclicos bicìclicos e o uso dos mesmos como inibidores de estaroil-coa-desaturase (scd)
DE60215028D1 (de) Indol derivate als beta-3-adrenerge agonisten zur behandlung von typ 2 diabetes
BRPI0509982A (pt) cepa isolada de escherichia coli, e, método para produzir um composto
PE20080834A1 (es) Derivados de eter diarilico antagonistas de receptores opioides
SE0401969D0 (sv) Piperidine derivatives
ATE453395T1 (de) 3, 7 oder 3 und 7 thia- oder oxaprostansäure derivate als mittel zur senkung des augeninnendrucks
EP1948161A4 (en) METHOD FOR PREVENTING AND TREATING PPAR-MEDIATED CONDITIONS WITH MACELIGNAN
BRPI0414241A (pt) composto, composição farmacêutica, métodos para ativar receptores 5-ht1f em um mamìfero, para inibir o extravasamento de proteìna neuronal em um mamìfero e para tratar ou prevenir enxaqueca em um mamìfero, e, uso de um composto
ES2545076T3 (es) Uso del inhibidor de HDAC panobinostat para el tratamiento de mieloma

Legal Events

Date Code Title Description
FB Suspension of granting procedure